DXCM vs SHC
Dexcom vs Sotera Health — AI-powered side-by-side comparison
| Metric | DXCM | SHC |
|---|
| AI Score |
65
|
56
|
| Price |
$89.16
|
$19.52
|
| P/E Ratio |
35.16×
|
33.44×
|
| ROE |
30.5%
|
12.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.5%
|
54.7%
|
| Debt / Equity |
0.53×
|
3.41×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.4
|
59.0
|
| Beta |
1.41
|
1.775
|
| Expected Upside |
+2.3%
|
+1.1%
|
AI Committee View
Current Innellis committee reasoning for DXCM versus SHC.
DXCM leads by 9 points.
DXCM scores 65/100 (Buy) versus SHC at 56/100 (Buy).
DXCM Committee View
67% agreement
6 analysts
The primary driver is eps growing 79.4% yoy. The main limiting factor is p/e of 34.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
SHC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 277.5% yoy. Risk Analyst remains cautious — high leverage (debt-to-equity 3.69) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 20.6% shows genuine earnings power backing the valuation — Value
- EPS growing 277.5% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 46.1 is expensive by classic value standards — Value
- Price-to-book of 8.3x prices in significant intangible value — Value
- Debt-to-equity of 3.69 adds balance-sheet risk to the value case — Value